Retinitis Pigmentosa Pipeline, Clinical Trials Studies, Emerging Drugs, Mergers and Acquisition, Licensing, Agreements & Collaborations, and Latest News 2023 (Updated)

 Breaking News
  • No posts were found

Retinitis Pigmentosa Pipeline, Clinical Trials Studies, Emerging Drugs, Mergers and Acquisition, Licensing, Agreements & Collaborations, and Latest News 2023 (Updated)

November 10
20:29 2023
Retinitis Pigmentosa Pipeline, Clinical Trials Studies, Emerging Drugs, Mergers and Acquisition, Licensing, Agreements & Collaborations, and Latest News 2023 (Updated)

DelveInsight’s “Retinitis Pigmentosa Pipeline Insight 2023” report provides comprehensive global Retinitis Pigmentosa coverage of available, marketed, and Retinitis Pigmentosa Pipeline therapies in various stages of Retinitis Pigmentosa clinical trials development, major pharmaceutical Retinitis Pigmentosa Companies are working to advance the Retinitis Pigmentosa pipeline space and future growth potential of the Retinitis Pigmentosa pipeline domain. 


Key takeaways from the Retinitis Pigmentosa Pipeline Report

  • Over 45+ Retinitis Pigmentosa companies are evaluating 45+ Retinitis Pigmentosa pipeline therapies in various stages of development, and their anticipated acceptance in the Retinitis Pigmentosa market would significantly increase market revenue.
  • The leading Retinitis Pigmentosa Companies includes Biogen, Neurotech, Ionis Pharmaceuticals, Novartis Pharmaceuticals, Nacuity Pharmaceuticals, ReNeuron, ID Pharma, Allegro Ophthalmics, SparingVision, Editas Medicine, OiDE OptoEye, and others.
  • Promising Retinitis Pigmentosa Pipeline Therapies include AAV2/5-RPGR, CPK850, Ophthalmic examinations, Mobility Test, NT-501, RST-001, and others.
  • The Retinitis Pigmentosa Companies and academics are working to assess challenges and seek opportunities that could influence Retinitis Pigmentosa R&D. The Retinitis Pigmentosa pipeline therapies under development are focused on novel approaches to treat/improve Retinitis Pigmentosa.
  • In November 2019, ProQR Therapeutics announced that it received Orphan Drug designation (ODD) from the Food and Drug Administration (FDA) for QR-1123. QR-1123 was in-licensed from Ionis Pharmaceuticals in 2018. QR-1123 has also received Fast Track designation from the FDA.


Request a sample and discover the recent breakthroughs happening in Retinitis Pigmentosa Pipeline Landscape @ Retinitis Pigmentosa Pipeline Outlook Report


Retinitis Pigmentosa Overview

Retinitis pigmentosa (RP) is an umbrella term for a group of hereditary progressive retinal disorders that cause progressive degeneration of the retina. The disease is inherited as autosomal recessive, autosomal dominant or X-linked recessive traits. Signs of retinitis pigmentosa usually appear during childhood or adolescence. Common symptoms include difficulty seeing at night and a loss of side (peripheral) vision. RP is diagnosed by electroretinography (ERG), visual field testing, and retinal imaging, fundus auto-fluorescence (FAF) and genetic testing. Currently, there is no therapy that stops the evolution of pigmentary retinopathies or restores the vision. Management of retinitis pigmentosa includes dietary supplements, ozone therapy, surgery etc. Gene therapy based treatments are under research focus for the treatment of Retinitis pigmentosa.


Retinitis Pigmentosa Emerging Drugs Profile

  • BIIB-112: Biogen
  • QR 1123 (formerly ISIS RHO 2.5Rx): Ionis Pharmaceuticals


Find out more about the Retinitis Pigmentosa Diagnosis and Treatment of patients @ Retinitis Pigmentosa Ongoing Clinical Trials Analysis


Retinitis Pigmentosa Companies and Pipeline Therapies

  • Biogen: AAV2/5-RPGR
  • Neurotech: CPK850
  • Ionis Pharmaceuticals: Ophthalmic examinations
  • Nacuity Pharmaceuticals: Mobility Test
  • Allegro Ophthalmics: NT-501
  • ID Pharma: RST-001


Retinitis Pigmentosa Pipeline Therapeutics Assessment


  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates


Route of Administration

  • Oral
  • Parenteral
  • Intravitreal
  • Subretinal
  • Topical


Molecule Type

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy
  • Product Type


Discover more about the list of Retinitis Pigmentosa FDA-approved drugs for Retinitis Pigmentosa @ Retinitis Pigmentosa Treatment Landscape


Scope of the Retinitis Pigmentosa Pipeline Report

  • Coverage- Global
  • Retinitis Pigmentosa Companies- Biogen (NYSE: BIIB), Neurotech International Inc (NYSE: NTI), Ionis Pharmaceuticals (NYSE: IONS), Novartis Pharmaceuticals (NYSE: NVS), Nacuity Pharmaceuticals, ReNeuron Group Inc (NYSE: RNUGF), ID Pharma, Allegro Ophthalmics, SparingVision, Editas Medicine (NYSE: EDIT), OiDE OptoEye, and others
  • Retinitis Pigmentosa Pipeline Therapies- AAV2/5-RPGR, CPK850, Ophthalmic examinations, Mobility Test, NT-501, RST-001, and others.
  • Retinitis Pigmentosa Pipeline Segmentation: Product Type, Molecule Type, Route of Administration, Mechanism of Action


Dive deep into rich insights for Retinitis Pigmentosa Emerging Therapies and Ongoing Clinical Trials; visit @ Retinitis Pigmentosa Emerging Therapies and Companies


Table of Content

  1. Introduction
  2. Retinitis Pigmentosa Executive Summary
  3. Retinitis Pigmentosa: Overview
  4. Retinitis Pigmentosa Pipeline Therapeutics
  5. Retinitis Pigmentosa Therapeutic Assessment
  6. Retinitis Pigmentosa – DelveInsight’s Analytical Perspective
  7. In-depth Commercial Assessment
  8. Retinitis Pigmentosa Collaboration Deals
  9. Late Stage Products (Phase III)
  10. Drug name: Company name
  11. Drug profiles in the detailed report…..
  12. Mid-Stage Products (Phase II)
  13. BIIB-112: Biogen
  14. Drug profiles in the detailed report…..
  15. Early Stage Products (Phase I) 
  16. N-acetylcysteine-amide: Nacuity Pharmaceuticals
  17. Drug profiles in the detailed report…..
  18. Preclinical and Discovery Stage Products
  19. SPVN 06: SparingVision
  20. Drug profiles in the detailed report…..
  21. Inactive Products
  22. Retinitis Pigmentosa Key Companies
  23. Retinitis Pigmentosa Key Products
  24. Retinitis Pigmentosa- Unmet Needs
  25. Retinitis Pigmentosa- Market Drivers and Barriers
  26. Retinitis Pigmentosa- Future Perspectives and Conclusion
  27. Retinitis Pigmentosa Analyst Views
  28. Retinitis Pigmentosa Key Companies
  29. Appendix


For further information on the Retinitis Pigmentosa Pipeline therapeutics, reach out @ Retinitis Pigmentosa Market Drivers and Barriers


About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States

Related Articles